acetylcysteine
Trade name: mucomyst
Approved
Sep 14, 1963
Acetylcysteine (also known as N-acetylcysteine or N-acetyl-L-cysteine or NAC) is primarily used as a mucolytic agent and in the management of acetaminophen poisoning. Acetylcysteine likely protects the liver by maintaining or restoring the glutathione levels, or by acting as an alternate substrate for conjugation with, and thus detoxification of, the reactive metabolite. Nacystelyn (NAL), a recently-developed lysine salt of N-acetylcysteine (NAC) is known to have excellent mucolytic capabilities and is used to treat cystic fibrosis (CF) lung disease. NAC as a precursor to the antioxidant glutathione modulates glutamatergic, neurotrophic, and inflammatory pathways. The potential applications of NAC to facilitate recovery after traumatic brain injury, cerebral ischemia, and in treatment of cerebrovascular vasospasm after subarachnoid hemorrhage. Acetylcysteine serves as a prodrug to L-cysteine, which is a precursor to the biologic antioxidant, glutathione, and hence administration of acetylcysteine replenishes glutathione stores. L-cysteine also serves as a precursor to cystine, which in turn serves as a substrate for the cystine-glutamate antiporter on astrocytes hence increasing glutamate release into the extracellular space. Acetylcysteine also possesses some anti-inflammatory effects possibly via inhibiting NF-κB through redox activation of the nuclear factor kappa kinases thereby modulating cytokine synthesis. NAC is associated with reduced levels of inflammatory cytokines and acts as a substrate for glutathione synthesis. These actions are believed to converge upon mechanisms promoting cell survival and growth factor synthesis, leading to increased neurite sprouting. — NCATS
Clinical trial activity
534 trials · 454 clinical orgs · 28 marketing orgs
Earliest trial started Jan 1, 1997 (NCT00205647)
Timeline
1960s
1990s
- Apr 30, 1992
Roxane Laboratories — Marketing Organization
- Apr 30, 1992
Boehringer Ingelheim — Marketing Organization
- Jul 28, 1995
Sankyo — Marketing Organization
- Jul 28, 1995
Lutipold — Marketing Organization
- Jan 1, 1997
Earliest Phase 2 Sponsor(trial)
- Jan 1, 1998
Earliest Phase 3 Sponsor(trial)
2000s
- Jan 1, 2003
Earliest Phase 1 Sponsor(trial)
- Jan 23, 2004
Cumberland Pharmaceuticals — NDA Secondary Org
2010s
- Jun 21, 2012
Alvogen — Marketing Organization
- Nov 7, 2012
Fresenius — Marketing Organization
- Mar 24, 2015
Akorn, Inc. — Marketing Organization
- Jun 19, 2015
Rising Pharmaceuticals — Marketing Organization
- Jun 19, 2015
Mylan — Marketing Organization
- Jan 29, 2016
Arbor Pharmaceuticals — NDA Secondary Org
- Feb 29, 2016
Aurobindo Pharma — Marketing Organization
- Feb 29, 2016
Eugia Pharma — Marketing Organization
- Oct 31, 2017
Sagent Pharmaceuticals, Inc. — Marketing Organization
- Oct 31, 2017
Nichi-Iko Pharmaceutical Co., Ltd. — Marketing Organization
- Jul 20, 2018
Zydus Discovery DMCC — Marketing Organization
2020s
- Apr 15, 2021
Exela Pharma Sciences, LLC. — Marketing Organization
- Feb 3, 2022
Aspen Pharmaceuticals — Marketing Organization
- Feb 3, 2022
Glenmark Pharmaceuticals — Marketing Organization
- Feb 23, 2022
Indoco Remedies — Marketing Organization
- Apr 19, 2023
STERISCIENCE — Marketing Organization
- Feb 13, 2024
GALEPHAR — Marketing Organization
- Jun 7, 2024
Somerset Pharmaceuticals — Marketing Organization
Indications
Approved for
Studied for
- Acetaminophen · Phase 3
- Acetylcysteine · Phase 4
- Acute Coronary Syndrome · Phase 3
- Acute Febrile Encephalopathy · Phase 2
- Acute Kidney Injury · Phase 4
- Acute Lung Injury · Phase 2
- Adenocarcinoma, Mucinous · Phase 1/Phase 2
- Adipose Tissue · Phase 4
- Adrenoleukodystrophy · Phase 2
- Affective Disorders, Psychotic · Phase 4
- Aging · Phase 1/Phase 2
- Albinism, Oculocutaneous · Phase 1/Phase 2
- Alcohol Drinking · Phase 2
- Alcohol-Induced Disorders · Phase 4
- Alcoholism · Phase 4
- Allografts · Phase 4
- Alopecia · Phase 4
- alpha-Mannosidosis · Phase 2
- Altitude Sickness · Phase 4
- Alzheimer Disease · Early Phase 1
- Analgesics, Opioid · Phase 4
- Anemia · Phase 4
- Anemia, Aplastic · Phase 2
- Anemia, Sickle Cell · Phase 3
- Anesthesia, General · Phase 1
- Angina Pectoris · Phase 2
- Angina, Stable · Phase 3
- Anosmia · Phase 3
- Antioxidants · Phase 4
- Arrhythmias, Cardiac · Phase 2
- Arthroplasty, Replacement, Knee · Phase 4
- Aspartylglucosaminuria · Phase 2
- Asperger Syndrome · Phase 2
- Asthma · Phase 4
- Atherosclerosis · Phase 4
- Atrial Fibrillation · Phase 3
- Autism Spectrum Disorder · Phase 4
- Autistic Disorder · Phase 4
- Bacterial Infections · Phase 4
- Behavior, Addictive · Phase 2
- beta-Thalassemia · Phase 3
- Biliary Atresia · Phase 2
- Biopsy · Phase 1
- Bipolar Disorder · Phase 4
- Blood · Early Phase 1
- Blood Platelet Disorders · Phase 2/Phase 3
- Blood Pressure · Phase 4
- Bone Marrow Diseases · Phase 1
- Borderline Personality Disorder · Phase 2
- Brain Death · Phase 3
- Brain Injuries · Phase 1/Phase 2
- Brain Injuries, Traumatic · Phase 2
- Brain Neoplasms · Phase 1
- Breast Diseases · Phase 4
- Breast Neoplasms · Phase 1
- Bronchiolitis · Phase 4
- Bronchitis, Chronic · Phase 4
- Bulimia Nervosa · Phase 3
- Calcium Hydroxide · Early Phase 1
- Cannabis · Phase 4
- Carcinoma, Bronchogenic · Phase 2
- Carcinoma, Hepatocellular · Phase 2
- Carcinoma, Ovarian Epithelial · Phase 1
- Cardiac Surgical Procedures · Phase 2
- Cardiomyopathy, Hypertrophic · Phase 1
- Cardiopulmonary Bypass · Phase 4
- Cardiovascular Diseases · Phase 4
- Carpal Tunnel Syndrome · Phase 4
- Catheter-Related Infections · Phase 3
- Catheters · Phase 3
- Cerebrospinal Fluid · Phase 1
- Cerebrospinal Fluid Otorrhea · Phase 4
- Child Development Disorders, Pervasive · Phase 2
- Chorioamnionitis · Phase 1/Phase 2
- Chronic Kidney Disease-Mineral and Bone Disorder · Phase 3
- Cocaine-Related Disorders · Phase 4
- Cognition Disorders · Phase 4
- Cognitive Dysfunction · Phase 1/Phase 2
- Common Cold · Phase 3
- Conjunctivitis · Phase 1
- Connective Tissue Diseases · Phase 2/Phase 3
- Contrast Media · Phase 4
- Coronary Artery Disease · Phase 4
- Coronary Disease · Phase 4
- Coronavirus Infections · Phase 4
- COVID-19 · Phase 4
- Craniocerebral Trauma · Phase 3
- Critical Illness · Phase 4
- Cystine · Early Phase 1
- Cystinosis · Phase 4
- Deafness · Phase 2/Phase 3
- Deficiency Diseases · Phase 2
- De Lange Syndrome · Phase 2
- Delivery, Obstetric · Phase 2/Phase 3
- Depression · Phase 2
- De Quervain Disease · Phase 2
- Dermatology · Phase 2
- Diabetes Mellitus · Phase 3
- Diabetes Mellitus, Type 1 · Phase 1/Phase 2
- Diabetes Mellitus, Type 2 · Phase 4
- Diabetic Foot · Phase 3
- Diabetic Nephropathies · Phase 2/Phase 3
- Diabetic Neuropathies · Phase 4
- Diabetic Retinopathy · Phase 1
- Dietary Supplements · Phase 4
- DNA Damage · Phase 1/Phase 2
- Drug Delivery Systems · Early Phase 1
- Drug Overdose · Phase 4
- Drug-Related Side Effects and Adverse Reactions · Phase 4
- Drug Resistant Epilepsy · Phase 2
- Dry Eye Syndromes · Phase 2
- Dupuytren Contracture · Phase 2
- Endocrine System Diseases · Phase 1/Phase 2
- Endodontics · Early Phase 1
- Endometriosis · Phase 3
- Endoscopy, Digestive System · Phase 2
- Endothelial Cells · Phase 1/Phase 2
- Enterocolitis, Necrotizing · Phase 4
- Erythrocytes, Abnormal · Phase 1
- Ethambutol · Phase 4
- Euthyroid Sick Syndromes · Phase 4
- Exercise · Phase 4
- Fallopian Tube Neoplasms · Phase 2
- Fasciitis, Plantar · Phase 2
- Fatigue · Phase 2
- Fatigue Syndrome, Chronic · Phase 2
- Fatty Liver · Phase 3
- Feeding and Eating Disorders · Early Phase 1
- Fibromyalgia · Phase 1/Phase 2
- Fractures, Bone · Phase 4
- Fuchs' Endothelial Dystrophy · Phase 2
- Fucosidosis · Phase 2
- Gambling · Phase 2
- Gastritis · Phase 2
- Gastrointestinal Neoplasms · Phase 2
- Gaucher Disease · Phase 2
- General Surgery · Phase 4
- Genetic Diseases, Inborn · Phase 2
- Glaucoma, Open-Angle · Phase 1
- Glioma · Phase 1
- Glucosephosphate Dehydrogenase Deficiency · Early Phase 1
- Graft vs Host Disease · Phase 3
- Hair · Phase 2
- Hamartoma · Phase 2
- Hand Injuries · Phase 4
- Head and Neck Neoplasms · Phase 4
- Healthy Volunteers · Phase 1
- Hearing Loss · Phase 4
- Hearing Loss, Noise-Induced · Phase 1
- Hearing Loss, Sensorineural · Phase 2/Phase 3
- Heart Defects, Congenital · Phase 2
- Heart Diseases · Phase 3
- Heart Failure · Phase 2/Phase 3
- Heart Valve Diseases · Phase 4
- Helicobacter pylori · Phase 4
- Hematologic Diseases · Phase 3
- Hematopoietic Stem Cell Transplantation · Phase 3
- Hepatectomy · Phase 4
- Hepatic Encephalopathy · Phase 3
- Hepatitis · Phase 2/Phase 3
- Hepatitis, Alcoholic · Phase 4
- Hermanski-Pudlak Syndrome · Phase 1/Phase 2
- HIV · Phase 1/Phase 2
- HIV Infections · Phase 1
- Hodgkin Disease · Phase 2
- Homocystinuria · Phase 2
- Huntington Disease · Phase 2
- Hypertension · Phase 4
- Hypoglycemia · Phase 1/Phase 2
- Hypotension · Phase 2
- Hypoxia · Phase 4
- Hysterectomy · Phase 3
- Idiopathic Pulmonary Fibrosis · Phase 3
- Infant, Premature · Phase 4
- Infections · Phase 3
- Infertility · Phase 3
- Infertility, Female · Phase 3
- Infertility, Male · Phase 1/Phase 2
- Inflammation · Phase 4
- Influenza, Human · Phase 4
- Intensive Care Units · Phase 4
- Iron Metabolism Disorders · Phase 2/Phase 3
- Irritable Bowel Syndrome · Phase 2
- Ischemic Stroke · Phase 2
- Jaundice · Phase 3
- Kidney Diseases · Phase 4
- Kidney Failure, Chronic · Phase 4
- Kidney Function Tests · Phase 2/Phase 3
- Kidney Transplantation · Phase 3
- Learning Disabilities · Phase 4
- Leiomyoma · Phase 2/Phase 3
- Leukemia · Phase 2
- Leukemia, Myeloid, Acute · Phase 2
- Leukodystrophy, Globoid Cell · Phase 2
- Leukodystrophy, Metachromatic · Phase 2
- Linezolid · Phase 4
- Liver Diseases · Phase 4
- Liver Failure · Phase 2
- Liver Failure, Acute · Phase 4
- Liver Neoplasms · Phase 2
- Liver Transplantation · Phase 3
- Lung Diseases · Phase 4
- Lung Diseases, Interstitial · Phase 2/Phase 3
- Lung Diseases, Obstructive · Phase 4
- Lung Neoplasms · Phase 4
- Lupus Erythematosus, Systemic · Phase 1/Phase 2
- Lymphoma · Phase 1
- Lymphoma, Non-Hodgkin · Phase 2
- Macular Degeneration · Phase 3
- Major Depressive Disorder · Early Phase 1
- Marijuana Abuse · Phase 4
- Melanoma · Phase 2
- Metabolic Diseases · Phase 2
- Metabolic Side Effects of Drugs and Substances · Phase 4
- Metabolic Syndrome · Phase 4
- Methamphetamine · Phase 2/Phase 3
- Migraine Disorders · Phase 3
- Mitochondrial Diseases · Phase 1
- Mood Disorders · Phase 4
- Morton Neuroma · Phase 2
- Mouth Diseases · Phase 2
- Mucopolysaccharidoses · Phase 2
- Mucopolysaccharidosis I · Phase 2
- Mucopolysaccharidosis II · Phase 2
- Mucopolysaccharidosis VI · Phase 2
- Mucopolysaccharidosis VII · Phase 2
- Mucositis · Phase 3
- Mucus · Phase 3
- Multiple Sclerosis · Phase 2
- Multiple Sclerosis, Chronic Progressive · Phase 2
- Muscle Weakness · Phase 1
- Musculoskeletal Diseases · Phase 2/Phase 3
- Mutation · Phase 2
- Myeloproliferative Disorders · Phase 1/Phase 2
- Myocardial Infarction · Phase 4
- Myocardial Ischemia · Phase 4
- Nail Biting · Phase 3
- Nasal Obstruction · Phase 4
- Neoplasms · Phase 2/Phase 3
- Nerve Fibers · Phase 4
- Neuralgia · Phase 2
- Neuroectodermal Tumors, Primitive · Phase 1
- Neurofibromatosis 1 · Phase 2
- Neuromuscular Diseases · Phase 1/Phase 2
- Niemann-Pick Disease, Type C · Phase 1/Phase 2
- Non-alcoholic Fatty Liver Disease · Phase 2
- Obesity · Phase 2
- Obsessive Behavior · Phase 4
- Obsessive-Compulsive Disorder · Phase 2
- Obstetric Labor, Premature · Phase 1/Phase 2
- Olfaction Disorders · Phase 3
- Opioid-Related Disorders · Early Phase 1
- Optic Atrophy · Phase 2/Phase 3
- Oral Ulcer · Phase 2
- Organophosphate Poisoning · Early Phase 1
- Organ Transplantation · Phase 3
- Osteoarthritis, Knee · Phase 4
- Osteopetrosis · Phase 2
- Osteosarcoma · Phase 1
- Otitis Media · Phase 4
- Otosclerosis · Phase 4
- Ototoxicity · Phase 4
- Ovarian Neoplasms · Phase 2
- Oxidative Stress · Phase 4
- Oxygen · Phase 4
- Pain · Phase 4
- Pancreatic Neoplasms · Phase 4
- Pancreatitis · Phase 4
- Paranasal Sinus Diseases · Phase 2
- Parkinson Disease · Phase 2
- Peptic Ulcer · Phase 2/Phase 3
- Peripheral Arterial Disease · Phase 1
- Peripheral Nervous System Diseases · Phase 2
- Peritoneal Dialysis · Phase 4
- Peroneal Neuropathies · Phase 2
- Peroxisomal Disorders · Phase 2
- Persian Gulf Syndrome · Phase 2
- Placebos · Phase 2
- Platelet Storage Pool Deficiency · Phase 1/Phase 2
- Pneumonia, Ventilator-Associated · Phase 1/Phase 2
- Poisoning · Phase 4
- Polycystic Ovary Syndrome · Phase 4
- Polycythemia · Phase 1/Phase 2
- Polycythemia Vera · Phase 1/Phase 2
- Polymorphism, Genetic · Phase 4
- Postoperative Complications · Phase 4
- Postoperative Pain · Phase 4
- Precursor Cell Lymphoblastic Leukemia-Lymphoma · Phase 4
- Premature Birth · Phase 4
- Premedication · Phase 2
- Primary Myelofibrosis · Phase 1/Phase 2
- Proteinuria · Phase 2
- Pruritus · Early Phase 1
- Pseudomyxoma Peritonei · Phase 1/Phase 2
- Psoriasis · Phase 3
- Psychiatry · Phase 2
- Psychomotor Performance · Phase 2
- Psychotic Disorders · Phase 4
- Pulmonary Atelectasis · Phase 4
- Pulmonary Disease, Chronic Obstructive · Phase 4
- Pulmonary Embolism · Phase 4
- Pulmonary Fibrosis · Phase 3
- Purpura, Thrombocytopenic · Early Phase 1
- Purpura, Thrombocytopenic, Idiopathic · Phase 2
- Purpura, Thrombotic Thrombocytopenic · Early Phase 1
- Pyelonephritis · Phase 2
- Quality of Life · Phase 4
- Recurrence · Phase 3
- Refsum Disease, Infantile · Phase 2
- Renal Artery Obstruction · Phase 4
- Renal Insufficiency · Phase 4
- Renal Insufficiency, Chronic · Phase 4
- Reperfusion Injury · Phase 4
- Respiration, Artificial · Phase 1
- Respiratory Distress Syndrome · Early Phase 1
- Respiratory Tract Diseases · Phase 3
- Respiratory Tract Infections · Phase 1
- Retinitis Pigmentosa · Phase 3
- Rhabdomyolysis · Phase 2
- Rhinitis, Allergic · Phase 1
- Rifampin · Phase 4
- Rotator Cuff Injuries · Phase 4
- Schizophrenia · Phase 4
- Scleroderma, Diffuse · Phase 2/Phase 3
- Self-Injurious Behavior · Phase 2
- Severe Acute Respiratory Syndrome · Phase 1
- Shock, Septic · Phase 3
- Simethicone · Phase 2
- Sinusitis · Phase 3
- Skin Diseases · Early Phase 1
- Smoking · Phase 2
- Sphingolipidoses · Phase 2
- Sphingomyelins · Phase 2
- Splints · Phase 4
- ST Elevation Myocardial Infarction · Phase 3
- Stomach Diseases · Phase 4
- Stomach Neoplasms · Phase 4
- Stomatitis · Phase 3
- Stress Disorders, Post-Traumatic · Phase 2
- Substance Abuse, Oral · Phase 2
- Substance-Related Disorders · Phase 4
- Suicide · Phase 2
- Systemic Inflammatory Response Syndrome · Phase 4
- Tarsal Tunnel Syndrome · Phase 2
- Thoracic Surgery · Phase 3
- Thrombocythemia, Essential · Phase 1/Phase 2
- Thrombocytopenia · Phase 4
- Thrombosis · Phase 3
- Thrombotic Microangiopathies · Phase 3
- Tics · Phase 2
- Tinnitus · Phase 4
- Tobacco Smoking · Phase 3
- Tobacco Use Disorder · Phase 4
- Tourette Syndrome · Phase 2
- Toxicity Tests · Phase 4
- Transposition of Great Vessels · Phase 2
- Trichotillomania · Phase 2
- Trigger Finger Disorder · Phase 2
- Tuberculosis · Phase 4
- Tuberculosis, Pulmonary · Phase 2
- Vaginosis, Bacterial · Phase 4
- Vagus Nerve Stimulation · Early Phase 1
- Vascular Grafting · Phase 3
- Ventilation · Phase 4
- Weight Loss · Phase 2
- Zellweger Syndrome · Phase 2
Mechanism of action
- Unspecified targetOTHER
Mycolytic
Mucolytic agent, cleaves disulfide linkages reducing mucous viscosity. May also have a role in managing the oxidant burden.
- Unspecified targetOTHER
Glutathione precursor
Antidote for acetaminophen overdose. Upon overdose, significant amounts of a reactive intermediate are formed which reacts with glutathione, depleting hepatic glutathione stores, and then reacts with hepatocyte proteins. Acetylcysteine provides an alternative substrate for conjugation with the reactive intermediate potentially restoring glutathione levels.
- Unspecified targetAntioxidant
antioxidant
Combination products
mucomyst w/ isoproterenol
with isoprenaline
Approval history
- approvedPriority reviewSep 14, 1963
Chemistry & pharmacology
SMILES
CC(=O)N[C@@H](CS)C(O)=O- Mol. weight
- 163.195 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Delivery
- Oral, Parenteral, Topical
- Availability
- Prescription Only
Oral
Yes
Parenteral
Yes
Topical
Yes
Sources
- WikipediaAcetylcysteine ↗
- NCATSWYQ7N0BPYC ↗
- ChEMBLCHEMBL6068327 ↗
- ChEMBLCHEMBL600 ↗
Also known as
- (2r)-2-acetylamino-3-sulfanylpropanoic acid
- (2r)-2-acetylamino-3-sulfanylpropanoic acid
- 5052
- acc-600
- acetadote
- acetadote
- acetadote
- acetadote
- acetilcisteina
- acetilcisteina
- acetilcysteina
- acetylcysteine
- acetylcysteine
- acetylcysteine
- acetylcysteine
- acetylcysteine
- acetylcysteine
- acetylcysteine
- acetylcysteine
- acetylcysteine
- acetylcysteine
- acetylcysteinum
- acetylcysteinum
- acteylcysteine
- a-cys
- airbron
- airbron
- ar10
- en-cys
- fabrol
- fabrol
- fluimucil
- fluimucil
- fluimucil
- fluimucil 600
- fluimucil long
- fluimucil n
- ilube
- ilube
- l-acetylcysteine
- l-acetylcysteine
- l-acetylcysteine
- l-α-acetamido-β-mercaptopropionic acid
- l-α-acetamido-β-mercaptopropionic acid
- mercapturic acid
- mercapturic acid
- mucomyst
- mucomyst
- mucosil
- mucosil
- mucosil-10
- mucosil-10
- mucosil-20
- mucosil-20
- nac
- nac
- n-acetylcysteine
- n-acetylcysteine
- n-acetylcysteine
- n-acetyl cysteine
- n-acetyl cysteine
- n-acetyl-cysteine
- n-acetyl-cysteine
- n-acetylcystine
- n-acetylcystine
- n-acetyl-l-cysteine
- n-acetyl-l-cysteine
- n-acetyl-l-cysteine
- n-acetyl-l-cysteine
- n-acetyl-l-(+)-cysteine
- n-acetyl-l-(+)-cysteine
- n-monoacetylcystine
- oronac 600
- parvolex
- parvolex
- parvolex
- (r)-2-acetylamino-3-mercaptopropanoic acid
- (r)-2-acetylamino-3-mercaptopropanoic acid
- respi-nac
- (r)-mercapturic acid
- (r)-mercapturic acid
- siran
- siran
- solmucol
- solmucol
- yournac
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07227649 | Phase 2 | Jan 15, 2026 | University of Arizona |
| NCT07301294 | Phase 4 | Jan 1, 2026 | Menoufia University |
| NCT07293884 | N/A | Dec 31, 2025 | Assiut University |
| NCT07049952 | Phase 2/Phase 3 (Phase 3) | Nov 16, 2025 | Medical University of South Carolina, National Institutes of Health (NIH) |
| NCT07262554 | Phase 2 | Nov 15, 2025 | Alexandria University |
| NCT06956482 | Phase 3 | Oct 31, 2025 | University of Lille |
| NCT07196852 | N/A | Sep 22, 2025 | University of Thessaly |
| NCT07156786 | Phase 2/Phase 3 (Phase 3) | Sep 15, 2025 | University of Indonesia |
| NCT07245095 | Phase 2 | Sep 12, 2025 | Hospital General de Mexicali |
| NCT07157722 | Phase 3 | Aug 30, 2025 | Mansoura University, Tanta University |
| NCT07058090 | Phase 1 | Jul 31, 2025 | Liaquat University of Medical & Health Sciences |
| NCT06890507 | Phase 2 | Jun 1, 2025 | University of Adelaide |
| NCT06909799 | N/A | Apr 28, 2025 | Aurum Institute, Ludwig Maximilians University, Research Center Borstel |
| NCT06727422 | Phase 2 | Apr 1, 2025 | Cedars-Sinai Medical Center |
| NCT06836128 | Phase 3 | Mar 1, 2025 | Cairo University |
| NCT06828120 | Phase 4 | Feb 20, 2025 | Government of China, Taipei Veteran General hospital |
| NCT06581783 | N/A | Nov 1, 2024 | Asian Institute of Gastroenterology |
| NCT06650384 | Phase 2/Phase 3 (Phase 3) | Nov 1, 2024 | Ain Shams University |
| NCT07229456 | Phase 3 | Oct 1, 2024 | Ain Shams University |
| NCT06546475 | Phase 4 | Aug 1, 2024 | National Taiwan University |
Organizations
Research & Development (454)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Medical University of South Carolina | Academic/Hospital | 24 | 12 | 4 | 2003 |
| Ain Shams University | Academic/Hospital | 19 | 17 | 5 | 2013 |
| Department of Veteran Affairs | Government | 17 | 10 | 5 | 2003 |
| National Institutes of Health (NIH) | Government | 17 | 1 | 5 | 2007 |
| University of Minnesota | Academic/Hospital | 13 | 9 | 4 | 2006 |
| Baylor University | Academic/Hospital | 12 | 12 | 3 | 2006 |
| Harvard University | Academic/Hospital | 12 | 9 | 3 | 2003 |
| University of South Carolina | Academic/Hospital | 12 | 12 | 4 | 2006 |
| Yale University | Academic/Hospital | 11 | 9 | 3 | 2006 |
| Assiut University | Academic/Hospital | 10 | 10 | 5 | 2007 |
| National Institute on Drug Abuse (NIDA) | Government | 9 | 1 | 3 | 2003 |
| University of California, San Francisco | Academic/Hospital | 9 | 8 | 3 | 2009 |
| University of Toronto | Academic/Hospital | 9 | 9 | 5 | 2002 |
| Cairo University | Academic/Hospital | 8 | 5 | 5 | 2015 |
| Stanford University | Academic/Hospital | 8 | 7 | 2 | 2008 |
| Tel Aviv University | Academic/Hospital | 8 | 7 | 4 | 2003 |
| University of Sao Paulo | Academic/Hospital | 8 | 8 | 3 | 2005 |
| Cornell University | Academic/Hospital | 7 | 5 | 2 | 1997 |
| National Institute of Neurological Disorders and Stroke (NINDS) | Government | 7 | 1 | 2 | 2008 |
| Peking University | Academic/Hospital | 7 | 7 | 2 | 2017 |
Marketing (33)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Akorn, Inc. | For profit | MKTG | Mar 24, 2015 |
| Akorn, Inc. | For profit | SYN | Mar 24, 2015 |
| Alvogen | For profit | MKTG | Jun 21, 2012 |
| Alvogen | For profit | SYN | Jun 21, 2012 |
| Apothecon | For profit | NDA2 | Sep 14, 1963 |
| Apothecon | For profit | NDA | Sep 14, 1963 |
| Arbor Pharmaceuticals | For profit | NDA2 | Jan 29, 2016 |
| Aspen Pharmaceuticals | For profit | MKTG | Feb 3, 2022 |
| Athenex, Inc. | For profit | MKTG | — |
| Aurobindo Pharma | For profit | MKTG | Feb 29, 2016 |
| Boehringer Ingelheim | For profit | MKTG | Apr 30, 1992 |
| Cumberland Pharmaceuticals | For profit | NDA2 | Jan 23, 2004 |
| Dey | For profit | MKTG | Oct 14, 1986 |
| Eugia Pharma | For profit | MKTG | Feb 29, 2016 |
| Exela Pharma Sciences, LLC. | For profit | MKTG | Apr 15, 2021 |
| Fresenius | For profit | MKTG | Nov 7, 2012 |
| GALEPHAR | For profit | MKTG | Feb 13, 2024 |
| Glenmark Pharmaceuticals | For profit | MKTG | Feb 3, 2022 |
| Hospira | For profit | MKTG | May 1, 1989 |
| Indoco Remedies | For profit | MKTG | Feb 23, 2022 |
| Lutipold | For profit | MKTG | Jul 28, 1995 |
| Mead Johnson | For profit | NDA2 | — |
| Mylan | For profit | MKTG | Jun 19, 2015 |
| Nichi-Iko Pharmaceutical Co., Ltd. | For profit | MKTG | Oct 31, 2017 |
| Rising Pharmaceuticals | For profit | MKTG | Jun 19, 2015 |
| Roxane Laboratories | For profit | MKTG | Apr 30, 1992 |
| STERISCIENCE | For profit | MKTG | Apr 19, 2023 |
| STERISCIENCE | For profit | SYN | Apr 19, 2023 |
| Sagent Pharmaceuticals, Inc. | For profit | SYN | Oct 31, 2017 |
| Sagent Pharmaceuticals, Inc. | For profit | MKTG | Oct 31, 2017 |
| Sankyo | For profit | MKTG | Jul 28, 1995 |
| Somerset Pharmaceuticals | For profit | MKTG | Jun 7, 2024 |
| Zydus Discovery DMCC | For profit | MKTG | Jul 20, 2018 |